Enanta Pharmaceuticals, Inc. announced the advancement of its zelicapavir clinical development program for the treatment of respiratory syncytial virus (RSV), including plans for a registrational Phase 2b/3 clinical trial in high-risk adults and a Phase 2b clinical trial in pediatric patients. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs for infectious diseases.
